DOCSLIB.ORG

IHC) Outreach Services

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IHC) Outreach Services IIImmunohistochemistry (IHC) Outreach Services Note type of fixative used if not neutral buffered formalin. Note type of tissue/specimen Unless specified otherwise, positive and negative controls react satisfactorily. Available Chromogen – All markers have been validated with 3,3’-Diaminobenzidine Tetrahydrochloride (DAB) which results in a brown/black precipitate. DAB is the routine chromogen. In addition, some markers have also been validated using the Fast Red (RED), which results in a red precipitate. If available with both chromogens and one is not selected, the def ault will be the DAB chromogen. Antibody Common Applications St aining Charac teristi cs Actin (muscl e sp eci fic ) Smoo th, ske letal & ca rdiac musc le Cytoplasm ic Actin (smoo th muscle ) Smoo th muscl e an d myoep itheli al cel ls Cytoplasm ic and memb rane ALK Pr otein ALK1 posi tive lymp homa s Cytoplasm ic and/or nuclea r Alph a-1-Antitr ypsi n Demo nstr ates A-1-AT in liver Cytoplasm ic (A-1-AT) Bcl-2 Oncop rotein Foll icula r lymph oma an d so ft tiss ue Cytoplasm ic tumors Bcl-6 Foll icula r lymph oma Nucl ear Ber-EP 4, Epithelia l Antige n Aden oca rcin oma vs. meso the liom a Memb rane and cytoplasm ic. The and epithelial tumors membrane staining is preferentially basolateral. Beta-Amyloid Pos t mo rt em dia gnos is of demen tia E xtr acel lular de pos ition (am yloid plaques), vascular deposition (amyloid angiopathy) BRS T-3, (B72.3) Aden oca rcin oma vs. meso the liom a Cel l su rfac e an d cytop la sm ic Beta -Catenin Desmoid type-fibromatosis, solid and Nuclear pseudopapillary tumors of pancreas . CD 1a Langerhan cells, thymic T-cells, Memb rane and weak ly cytoplasm ic thymoma CD3 T-cells , lymp hom a/leuk emi a typin g Memb rane CD4 Helper/Inducer T-cells mycosis Memb rane fungoides vs. cutaneous inflammatory processes, lymphoma/ leukemia typing CD5 T-cell , lymphoma /le ukemi a typin g Memb rane CD8 T-cel l supp resso r/ cytoto xic , Memb rane lymphoma/leukemia typing, mycosis fungoides vs. cutaneous inflammatory processes CD 10 Lymph oma typing , me tas tatic Cytoplasm ic and Memb rane carcinoma unknown primary CD 15 Hodgkin Lymphoma Typing, Reed -St ernbe rg cell s in Hodgkin’ s mesothelioma vs. adenocarcinoma lymphoma show cell membrane and granular paranuclear staining. CD 20 , B C el l Lymph oma /le ukem ia typing Cytoplasmic side of the cell surface membrane CD21 Follicular Dendritic cell marker, found Cytoplasmic & Membrane also on some B cells CD 23 Lymph oma /le ukem ia typing Cytoplasm ic/memb ran e Antibody Common Applications St aining Charac teristi cs Revised 12/4/19 Page 1 of 6 L. Bliven CD 30 Anapl astic la rge cel l lymph oma, Memb rane and/or a dot like cytopl asmi c Hodgkin lymphoma staining CD 31 Endo thel ial Cells Pr edomina tel y cell memb rane , with weaker cytoplasmic staining. CD 34 Soft tissu e tumo r cla ssi fica tio n, Memb rane/cytoplasm ic leukemia typing CD 43 T-cell , lymphoma /le ukemi a typin g Pr edomin antly confine d to the cel l surface CD 45 (LCA) Lympho hema topoe tic tumo rs Memb rane, but cytoplasm ic may als o occur CD 56 NK cel ls, tum ors de rived from Memb rane neuroectodermal tumors such as CD 57 Lneuymphroeondmoac tryinpeing an, dneu neruorenobdlaosc tromin ea s, Cytoplasm ic and memb ran e differentiation CD 68 , PG- M1, Mac rop hag e His tiocytic /monoc ytic ma rke r Cell s of mon ocyte/mac roph ag e li nea ge stain diffuse or granular cytoplasmic. Mast CD 79 a B-cel l, lymphoma /le ukem ia typin g Ccelellls Maembre neragnaeti vaen. d/or cytopl asm CD 99 , SEE MIC2 CD 11 7 (c-ki t) Gas tr ointes tinal Str omal Tum ors Memb rane and/or cytopl asmi c (GIST), Mast Cells, Stains approximately 75% of mesenteric fibromatosis tumors. CD 13 8 Synd eca n-1 Plasm a Cell s (also stains en dothe lia l Cel l Memb rane, pre-B cell an d pl asm a cells, fibroblasts, keratinocytes, and cell marker, but is absent from mature B CD 16 3 Hno is rtmioacly htiecpa Letocsi oyntess ) Mcelembls. Irta ins ea se lec tive ma rke r for B ce ll CDX2 Colo n an d othe r GI ca nce rs are str on g Nucl eus in no rmal and neop lastic & diffusely positive. Also, mucinous intestinal epithelial cells. Calci ton in Moveadrulia lna rcay Tnhceyros ida reC aprocisintomivea. Neg for Cytoplasm ic Cal retini n Meso theli oma vs. ad enoca rci n oma , Cytoplasm ic and nucl ear sex cord stromal, adrenal tum ors, & Carci noemb ryon ic Antigen , CEA/M MHesoirsc hthperuli onmg’ as vcsa.s Aesde. Pnocleaasrec isnpecomaific, y Cytoplasm ic. Norma l co lon-CEA is metastatic carcinoma of unknown mainly localized at the apical border of the Carci noemb ryon ic Antigen , CEA/P Hprepaima tryom a vs. ad enoca rcinoma Cepyittoplasmheli al celic.l sIn. C li ovelo r,n pcarerdcoinomminana- tly bilary canaliculi are labeled. In colonic Chrom ogran in A Neu roe ndoc rin e di fferen tiation Cadenytoplasmoca rciinc om a the stain ing reac tio n is Cycli n D1 Man tle cel l lymphom a Nucl ear Cytoke ratin 5/6 Meso theli oma vs. Ade noc arcinom a Cytoplasm ic Cytoke ratin 7 Metastatic carcinoma of unknown Cytoplasmic. E xceptions to reactivity may primary occur e.g. CK-7 positive hepatocytes have been observed in patients with acute and chronic cholestasis. Cytok eratin 20 Metastatic carcinoma of unknown Cytoplasm ic. May occasio nall y be primary e xpressed in breast and lung adenocarcinomas, and in squamous cell carcinomas. Less than 5% CK20 positive cells may be present in a number of tissues not generally considered CK 20 positive. CK 11 6 – MNF 11 6 Epi theli al ma rke r Cytoplasm ic Cytoke ratin 34 BE12 Prostate basal cells, squamous cells Cytoplasm ic vs. adenocarcinoma Cytoke ratin , AE1/AE3 Epi theli al tumo rs, hepa tom a vs. Cytoplasm ic adenocarcinoma Cytoke ratin , CA M5.2 Epi theli al tumo rs Cytoplasm ic Revised 12/4/19 Page 2 of 6 L. Bliven Antibody Common Applications St aining Charac teristi cs Cytoke ratin Cock tail (K erCK) Epi theli al tumo rs Cytoplasm ic Cytomega lovi rus /IHC Cytomega lovi rus Nucl ear stai nin g pa ttern in ea rly HC MV infection, later stage, cytoplasmic staining might be observed. Does not x- react with adenovirus, herpes simplex virus, & varicella zoster virus. D2-40 Lympha tic end otheli um, Cytoplasm ic and some tim es memb rane mesothelioma vs. adenocarcinoma Desm in Smoo th and ske letal musc le Cytoplasm ic, may sh ow a fibrilla ry differentiation aspect. Eps tein -Barr Virus (EBV) RNA CISH La ten t EBV in fec tio n Nucl ear. Surgical /H ema topa th olog y consultation and review of the entire case is highly recommended. E-Cadhe rin Lobu lar vs. duc tal breast ca rcinom a Cellu lar mem bran e, some cytoplasm ic Epi theli al Memb ran e Antigen (E MA) Metas tatic ca rci nom a of unk nown In ne opl asms , cytop la sm ic and ap ica l primary, lymphoma luminal membrane staining are the most common patterns of immunoreactivity with peripheral membrane staining or other patterns also occurring. Plasma cells stain positive. In normal breast and other secretory epithelia, labeling is predominantly localized to apical luminal membranes. Estr ogen Recep tor (ERA) Br eas t ca rci nom a prognostic ma rke r, Nucl ear, cytopl asmi c is co nsi dered no n- metastatic carcinoma of unknown specific Occasional lymphoid tumors and primary non-lymphoid neoplasms such as melanomas are labeled. Follow CAP & ASCO guidelines. Fac tor VIII Rela ted Ag (Von Megaka ryoc ytic an d endo the lial Cytoplas m as diffu se or some tim es W illebrand Factor) marker slightly granular staining GATA-3 Ur ot heli al ca rci noma , breast ducta l Mus t be nuc le ar, stron g or mode rate epithelium, and transitional cells intensity, and non-focal in urothelial carcinoma. Glia l Fib rilla ry Acid ic Pr otei n GFAP Glia l tumo rs Cytoplasm ic Aceton e fixed fro zen or Bouins fixed tissues label certain neuronal structures, including a xons, indicting a X-r xn w/ neurofilam ent Glypican -3 Hepatocellular carcinoma vs. benign Granula r cytop lasm ic, and memb ranous hepatocellular lesions Patterns Yolk Sac Tumor, Choriocarcinoma Helicob acter P ylo ri Helicob acter pylo ri in fection Indi vid ual H. pylo ri bac terium when present on the surface of the epithelium or in the cytoplasm of the epithelial cells. ASR Hemo glob in A Er ythoi d ma rker Cytoplasm ic Revised 12/4/19 Page 3 of 6 L. Bliven Antibody Common Applications St aining Charac teristi cs Hep Par1 (H ep Ab) Hepa toma , gas tric ca rci nom a Disp lays a dis tinct, gran ula r cytopl asmi c staining pattern, which is occasionally ring- like and is present diffusely throughout the hepatocyte cytoplasm HER 2/NEU c -erbB -2 Oncoprotein HER-2/neu overexpression for invasive Follo w CAP an d ASCO guid elines for breast and gastric cancers.
Load more

Recommended publications
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • Induces Antigen Presentation in B Cells Cell-Activating Factor of The
    B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells This information is current as of September 27, 2021. Min Yang, Hidenori Hase, Diana Legarda-Addison, Leena Varughese, Brian Seed and Adrian T. Ting J Immunol 2005; 175:2814-2824; ; doi: 10.4049/jimmunol.175.5.2814 http://www.jimmunol.org/content/175/5/2814 Downloaded from References This article cites 54 articles, 36 of which you can access for free at: http://www.jimmunol.org/content/175/5/2814.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells1 Min Yang,* Hidenori Hase,* Diana Legarda-Addison,* Leena Varughese,* Brian Seed,† and Adrian T.
    [Show full text]
  • CD43 Expression in Malignant Melanoma: a Diagnostic Pitfall
    Asian Archives of Pathology 2014; Vol. 10 No.4, 97-109 Case Report CD43 Expression in Malignant Melanoma: A Diagnostic Pitfall Sanya Sukpanichnant Received: 24 September 2014; accepted 30 October 2014. ABSTRACT CD43 is commonly concerned as a marker for hematopoietic cells and, at times, a preferential T-cell marker. However, a number of non-hematologic cancers, mostly carcinoma, can express CD43. Recently, a case of malignant melanoma mimicking malignant lymphoma by cytomorphology was reported to express CD43 as well as melanoma markers but the other hematologic markers [Buehler et al. Diagn Cytopathol 2012;40:619- 23]. This is another case report. A 52-year-old man suffered from a rapidly growing left tonsillar mass for one month causing slurred speech. An incisional biopsy showed gray tissue and, beneath the epithelium, a sheet of - lastic lymphoma, as the original workup showed focal and faint CD138 expression but negative keratins and CD45. On consultation, hematologic malignancy and malignant melanoma were considered. The tumor cells express CD43, CD68 (focal), S-100, HMB45, Melan A, and vimentin. The negative markers included CD3, CD20, CD30, CD79a, MUM1, PAX5, kappa, lambda, and CK5/6. The proliferation index was high (70-75%) another case report of malignant melanoma with CD43 expression, mimicking malignant lymphoma, raises the awareness of diagnostic pitfall when dealing with undifferentiated tumors showing only CD43 expression among various hematologic markers. A panel for keratins, vimentin, S-100, CD45, CD30, and CD138 will be helpful when dealing with undifferentiated large cell tumor. Keywords: melanoma *This case report has been presented partly in a poster session in the 12th Japanese-Korean Lymphoreticular- Workshop 2014 in conjunction with the 5th Asian Hematopathology Symposium on January 25, 2014 at Nagoya University Hospital Lecture Hall.
    [Show full text]
  • Altered O-Glycan Synthesis in Lymphocytes from Patients with Wiskott-Aldrich Syndrome by Friedrich Piller,* Frangoise Le Deist, Kenneth 1
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Altered O-Glycan Synthesis in Lymphocytes from Patients with Wiskott-Aldrich Syndrome By Friedrich Piller,* Frangoise Le Deist, Kenneth 1 . Weinberg,§ Robertson Parkman,S and Minoru Fukuda* From the *La Jolla Cancer Research Foundation, La Jolla, California 92037, the #INSERM U132, Hopital Necker/Enfants Malades, F7S01S Paris, France; and the §Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital, Los Angeles, California 90033 Summary The only molecular defect reported for the X-linked immunodeficiency WiskottAldrich syndrome (WAS) is the abnormal electrophoretic behavior of the major T lymphocyte sialoglycoprotein CD43. Since the 70 to 80 O-linked carbohydrate chains of CD43 are known to influence markedly its electrophoretic mobility, we analyzed the structure and the biosynthesis of O-glycans of CD43 in lymphocytes from patients with WAS. Immunofluorescence analysis with the carbohydrate dependent anti-CD43 antibody T305 revealed that in 10 out ofthe 12 WAS patients tested increased numbers ofT lymphocytes carry on CD43 an epitope which on normal lymphocytes is expressed only after activation. Other activation antigens were absent from WAS lymphocytes . Western blots of WAS cell lysates displayed a high molecular mass form of CD43 which reacted with the T305 antibody and which could be found on in vivo activated lymphocytes but was absent from normal unstimulated lymphocytes. To examine the O-glycan structures, carbohydrate labeled CD43 was immunoprecipitated and the released oligosaccharides identified. WAS lymphocyte CD43 was found to carry predominantly the branched structure NeuNAca2-3Gala1--"3 (NeuNAca2-3Ga101-4G1cNAc01-6) Ga1NAcOH whereas normal lymphocytes carry the structure NeuNAca2-3Ga101--"3 (NeuNAca2--"6) Ga1NAcOH.
    [Show full text]
  • SUPPLEMENTARY APPENDIX Improved Classification of Leukemic B-Cell Lymphoproliferative Disorders Using a Transcriptional and Genetic Classifier
    SUPPLEMENTARY APPENDIX Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier Alba Navarro, 1,2* Guillem Clot, 1,2* Alejandra Martínez-Trillos, 1,2 Magda Pinyol, 2,3 Pedro Jares, 1,2 Blanca González-Farré, 1,2 Daniel Martínez, 1,2 Nicola Trim, 4 Verónica Fernández, 1 Neus Villamor, 1,2 Dolors Colomer, 1,2 Dolors Costa, 1,2 Itziar Salaverria, 1,2 , David Martín- Garcia, 1,2 Wendy Erber, 5 Cristina López, 6,7 Sandrine Jayne, 8 Reiner Siebert, 6,7 Martin J. S. Dyer, 8 Adrian Wiestner, 9 Wyndham H. Wilson, 10 Marta Aymerich, 1,2 Armando López-Guillermo, 1,2 Àlex Sánchez, 11,12 Elías Campo, 1,2 Estella Matutes 2 and Sílvia Beà 1,2 *AN and GC contributed equally to this work 1Institut d’Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Spain; 2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain; 3Genomics Unit, IDIBAPS, Barcelona, Spain; 4West Midlands Regional Genetics Laboratory, Birmingham, UK; 5School of Pathology and Laboratory Medicine, The University of Western Australia, Crawley, WA, Australia; 6Institute of Human Genetics, University Kiel, Germany; 7In - stitute of Human Genetics, University Hospital of Ulm, Germany; 8Ernest and Helen Scott Haematological Research Institute, Department of Biochemistry, Uni - versity of Leicester, UK; 9National Heart, Lung, and Blood Institute, Bethesda, MD, USA; 10 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; 11 Department of Genetics Microbiology and Statistics, University of Barcelona, Spain and 12 Statistic and Bioin - formatics Unit, Vall d’Hebron Research Institute, Barcelona, Spain Correspondence: [email protected] doi:10.3324/haematol.2016.160374 SUPPLEMENTARY INFORMATION Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier Navarro A & Clot G, et al.
    [Show full text]
  • The Role of Nucleolin in B-Cell Lymphomas and Fas-Mediated Apoptotic Signaling
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 5-2013 The Role of Nucleolin in B-cell Lymphomas and Fas-Mediated Apoptotic Signaling Jillian F. Wise Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Cancer Biology Commons, and the Medicine and Health Sciences Commons Recommended Citation Wise, Jillian F., "The Role of Nucleolin in B-cell Lymphomas and Fas-Mediated Apoptotic Signaling" (2013). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 339. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/339 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. The Role of Nucleolin in B-cell Lymphomas and Fas-Mediated Apoptotic Signaling by Jillian F Wise, BS Approved: ___________________________________________________ Felipe
    [Show full text]
  • An Overview of B Cells – from Discovery to Therapy Mini Review
    An Overview of B Cells – from Discovery to Therapy Mini Review Immunology In the past two decades, significant advances have been made in B cell biology. These critical immune cells remain an active area of research particularly because disruption of B cell development or function results in a number of autoimmune diseases and malignancies. In addition to producing antibodies, B cells are professional antigen presenting cells that can present antigens to T cells to generate effective immune responses. B cells are however, a heterogeneous population of cells at different stages of maturation along the lineage, each with unique functional properties. This mini-review provides a brief history of the discovery of B cells, as well as describes the characteristics of each B cell lineage and the processes of B cell development, maturation and activation. Finally, we highlight the application of B cell biology in the development of novel therapeutics for the treatment of B cell mediated diseases. Contents 1. A brief history of the discovery of B cells 2. B cell development and maturation 3. B cell activation and the humoral immune response 4. B cells as therapeutic targets 1. A brief history of the discovery of B cells B cells are an integral part of the adaptive immune response. They represent a distinct lineage, with separate and unique functions from T cells. In addition to producing antibodies, they perform critical immune functions such as generating immunological memory, antigen presentation and regulatory cytokine production. Our current understanding of B cell biology was initiated in 1965 with a landmark study by Max Cooper and Robert Good.
    [Show full text]
  • Reproducible Diagnosis of CLL by Flow Cytometry: an ERIC & ESCCA
    Reproducible diagnosis of CLL by flow cytometry: an ERIC & ESCCA harmonisation project Andy C. Rawstron, Karl-Anton Kreuzer, Asha Soosapilla, Martin Spacek, Peter Gambell, Neil McIver-Brown, Katherina Psarra, Maria Arroz, Raffaella Milani, Javier de la Serna, M. Teresa Cedena, Ozren Jaksic, Josep Nomdedeu, Carol Moreno, Gian Matteo Rigolin, Antonio Cuneo, Preben Johansen, Hans Johnsen, Richard Rosenquist Brandell, Carston Utoft Niemann, David Westerman, Marek Trneny, Stephen Mulligan, Peter Hillmen, David Oscier, Michael Hallek, Paolo Ghia, Emili Montserrat. On behalf of the European Research Initiated on CLL (ERIC) and the European Society for Clinical Cell Analysis (ESCCA) Current criteria: flexibility in marker expression • WHO criteria: • IWCLL guidelines: • CLL cells usually co-express CD5 and • CLL cells co-express the T-cell CD23 antigen CD5 and B-cell surface • Using flow cytometry, the tumour cells antigens CD19, CD20, and CD23. express dim surface IgM/IgD, CD20, CD22, CD5, CD19, CD79a, CD23, CD43 • The levels of surface Ig, CD20, & and CD11c (weak). CD10 is negative CD79b are characteristically low. and FMC& and CD79b are usually negative or weakly expressed in typical • Each clone is restricted to expression CLL. of either kappa or lambda. • Some cases may have an atypical • Variations of the intensity of immunophenotype (e.g. CD5- or expression of these markers may CD23-, FMC7+ or CD11c+, strong sIg, or CD79b+). exist and do not prevent inclusion of a patient in clinical trials for CLL. Trial cases referred to a central lab: ~2-5% not CLL & ~2-5% sub-optimal for MRD monitoring but this may vary according to trial treatment options • ADMIRE/ARCTIC trial: FCR-based treatment (n=421) • 97% typical phenotype (2% with no CD200 or CD43 expression) • 3% CD23neg, usually with additional aberrant markers but no t(11;14).
    [Show full text]
  • Chimeric Antigen Receptor Macrophage Therapy for Breast Tumours Mediated by Targeting the Tumour Extracellular Matrix
    www.nature.com/bjc ARTICLE Translational Therapeutics Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix Wenlong Zhang1, Ling Liu1, HuiFang Su1, Qin Liu2, Jie Shen2, Hanren Dai1, Wei Zheng1,YanLu1, Weijie Zhang3, Yuncheng Bei4 and Pingping Shen1 BACKGROUND: The extracellular matrix (ECM) is essential for malignant tumour progression, as it is a physical barrier to various kinds of anticancer therapies. Matrix metalloproteinase (MMPs) can degrade almost all ECM components, and macrophages are an important source of MMPs. Studies using macrophages to treat tumours have shown that macrophages can enter tumour tissue to play a regulatory role. METHODS: We modified macrophages with a designed chimeric antigen receptor (CAR), which could be activated after recognition of the tumour antigen HER2 to trigger the internal signalling of CD147 and increase the expression of MMPs. RESULTS: Although CAR-147 macrophage treatment did not affect tumour cell growth in vitro compared with control treatment. However, we found that the infusion of CAR-147 macrophages significantly inhibited HER2-4T1 tumour growth in BALB/c mice. Further investigation showed that CAR-147 macrophages could reduce tumour collagen deposition and promote T-cell infiltration into tumours, which were consistent with expectations. Interestingly, the levels of the inflammatory cytokines TNF-α and IL-6, which are key factors in cytokine release syndrome, were significantly decreased in the peripheral blood in CAR-147 macrophage- transfused mice. CONCLUSION: Our data suggest that targeting the ECM by engineered macrophages would be an effective treatment strategy for solid tumours. British Journal of Cancer (2019) 121:837–845; https://doi.org/10.1038/s41416-019-0578-3 BACKGROUND pressure further prevents the extravasation of T cells.
    [Show full text]
  • Signaling by the Epstein–Barr Virus LMP1 Protein Induces Potent
    Signaling by the Epstein–Barr virus LMP1 protein + + induces potent cytotoxic CD4 and CD8 T cell responses Il-Kyu Choia,b, Zhe Wanga,b, Qiang Kea,c, Min Honga,d, Yu Qiana,b, Xiujuan Zhaoa,e, Yuting Liuf, Hye-Jung Kimg, Jerome Ritza,b, Harvey Cantorg, Klaus Rajewskyh,1, Kai W. Wucherpfennigg, and Baochun Zhanga,b,g,1 aDepartment of Medical Oncology, Dana–Farber Cancer Institute, Boston, MA 02215; bDepartment of Medicine, Harvard Medical School, Boston, MA 02115; cDepartment of Diagnostics, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; dDepartment of Medical Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, China; eDepartment of Cell Biology, Tianjin Medical University, Tianjin 300070, China; fProgram in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, MA 02115; gDepartment of Cancer Immunology and Virology, Dana–Farber Cancer Institute, Boston, MA 02215; and hImmune Regulation and Cancer, Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany Contributed by Klaus Rajewsky, December 9, 2017 (sent for review August 3, 2017; reviewed by Alan B. Rickinson and Susan L. Swain) The B-lymphotropic Epstein–Barr virus (EBV), pandemic in humans, pressive molecules that foster local immune privilege (9, 10). is rapidly controlled on initial infection by T cell surveillance; there- Apparently, host immune cells, particularly T cells, keep EBV- after, the virus establishes a lifelong latent infection in the host. If infected cells under constant surveillance, and EBV-driven ma- surveillance fails, fatal lymphoproliferation and lymphomagenesis + lignancies only arise when surveillance fails. ensue. The initial T cell response consists of predominantly CD8 + T cell responses against EBV-infected or transformed B cells cytotoxic T cells and a smaller expansion of CD4 cells.
    [Show full text]
  • BAFF and APRIL Expression in B Cells in Vitro and in Vivo
    In Vitro and In Vivo Activation Induces BAFF and APRIL Expression in B Cells Van Trung Chu, Philipp Enghard, Gabriela Riemekasten and Claudia Berek This information is current as of September 27, 2021. J Immunol 2007; 179:5947-5957; ; doi: 10.4049/jimmunol.179.9.5947 http://www.jimmunol.org/content/179/9/5947 Downloaded from References This article cites 40 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/179/9/5947.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 27, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology In Vitro and In Vivo Activation Induces BAFF and APRIL Expression in B Cells1 Van Trung Chu,* Philipp Enghard,† Gabriela Riemekasten,† and Claudia Berek2* B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) play key roles in peripheral B cell survival, maturation, and differentiation.
    [Show full text]
  • Concentration of an Integral Membrane Protein, CD43
    Concentration of an Integral Membrane Protein, CD43 (Leukosialin, Sialophofin), in the Cleavage Furrow through the Interaction of Its Cytoplasmic Domain with Actin-based Cytoskeletons Shigenobu Yonemura,* Akira Nagafuchi,* Naruki Sato,** and Shoichiro Tsukita*r * Laboratory of Cell Biology, Department of Information Physiology,National Institute for Physiological Sciences, Okazaki, Aichi 444, Japan; and *Department of Physiological Sciences, School of Life Science, The Graduate University of Advanced Studies, Myodaiji-cho, Okazaki, Aichi 444, Japan Abstract. In leukocytes such as thymocytes and consisting of the extracellular domain of mouse Downloaded from http://rupress.org/jcb/article-pdf/120/2/437/1256004/437.pdf by guest on 24 September 2021 basophilic leukemia cells, a glycosilated integral mem- E-cadherin and the transmembrane/cytoplasmic do- brane protein called CIM3 (leukosialin or sialopho- main of rat CD43, and introduced it into mouse L rin), which is defective in patients with Wiskott- fibroblasts lacking both endogenous CD43 and Aldrich syndrome, was highly concentrated in the E-cadherin. In dividing transfectants, the chimeric cleavage furrow during cytokinesis. Not only at the molecules were concentrated in the cleavage furrow mitotic phase but also at interphase, CIM3 was pre- together with ERM, and both proteins were precisely cisely colocalized with ezrin-radixin-moesin family colocalized throughout the cell cycle. Furthermore, members (ERM), which were previously reported to using this transfection system, we narrowed down the play an important role in the plasma membrane-actin domain responsible for the CD43-concentration in the filament association in general. At the electron micro- cleavage furrow. Based on these findings, we conclude scopic level, throughout the cell cycle, both CIM3 and that CD43 is concentrated in the cleavage furrow ERM were tightly associated with microvilli, provid- through the direct or indirect interaction of its cyto- ing membrane attachment sites for actin filaments.
    [Show full text]